Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6WN | ISIN: US0197701065 | Ticker-Symbol:
NASDAQ
31.03.25
21:45 Uhr
1,470 US-Dollar
-0,085
-5,47 %
1-Jahres-Chart
ALLOGENE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ALLOGENE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur ALLOGENE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.03.Citi maintains Buy on Allogene stock with $8 price target16
14.03.Allogene upgraded at Citizens after Q4 update4
14.03.Allogene's Q4 Loss Narrower Than Expected, Revenues Nil3
14.03.Allogene stock rating upgraded, price target set at $5 by Citizens JMP1
13.03.Allogene Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans5
13.03.Allogene Therapeutics GAAP EPS of -$0.28 beats by $0.052
13.03.Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update144Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase...
► Artikel lesen
ALLOGENE THERAPEUTICS Aktie jetzt für 0€ handeln
13.03.Allogene Therapeutics, Inc. - 10-K, Annual Report2
13.03.Allogene Therapeutics, Inc. - 8-K, Current Report1
03.03.Allogene Therapeutics, Inc.: Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update6
25.02.Allogene Therapeutics, Inc.: Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia104SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
► Artikel lesen
25.02.Allogene Therapeutics, Inc. - 8-K, Current Report1
14.02.Allogene's phase 1 lymphoma data show CAR-T could 'leapfrog' competition: analysts12
13.02.Allogene meldet vielversprechende Ergebnisse für CAR-T-Therapie bei Lymphom20
13.02.Allogene Therapeutics, Inc.: Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in ...2
29.01.FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases4
29.01.Allogene Therapeutics, Inc.: Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer550SOUTH SAN FRANCISCO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
► Artikel lesen
29.01.Allogene Therapeutics, Inc. - 8-K, Current Report1
28.01.Allogene gains FDA IND clearance for CAR T candidate for lupus1
28.01.Allogene Therapeutics, Inc.: Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases128Dual-Targeted CD19/CD70 Allogeneic CAR T: Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease IndicationsInnovative Dagger® Technology:...
► Artikel lesen
Seite:  Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1